Scythian Biosciences Corp. announced Brady Cobb has been appointed Chief Executive Officer. Effective October 3, 2018, Mr. Cobb replaces Rob Reid, who has stepped down to focus on European Cannabis Investment opportunities and will remain as an active member of the Board of Directors and key person in driving the company's strategic direction.

In addition, the company has named Chairman Andy DeFrancesco to the position of Chief Investment Officer effective November 1, 2018. In this role, Andy will continue driving Scythian's strategic plan through identifying and evaluating expansion opportunities accretive to the company's existing holdings throughout the United States and beyond to ensure further value creation and growth in stockholder value. Mr. Cobb was Chief Legal Officer for Liberty Health Sciences Inc. (LHS:CSE) through July of 2018, and has owned and operated his South Florida based boutique business and governmental relations law firm since 2012.

Prior to forming Cobb Eddy, PLLC, Cobb served as a director at Tripp Scott, P.A.